Marshall Wace
APTO

Marshall Wace’s Aptose Biosciences, Inc. APTO Stock Holding History

Marshall Wace’s Portfolio APTO Stock Details APTO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,477
Closed -$3.97M – 3276
2021
Q1 		$3.97M Buy
1,477
+1,248
+545% +$2.47M 0.02% 965
2020
Q4 		$451K Buy
+229
New +$538K ﹤0.01% 1498

Other funds holding APTO

DS
DRW Securities Chicago, Illinois $7.21B AUM 20.54% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SMH
Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $36.7M AUM 6.81% 1-Year Est. Return

Marshall Wace's APTO Position: Q2 2021 in Review

Marshall Wace sold out of Aptose Biosciences, Inc. (APTO) in Q2 2021, closing a stake of 1,477 shares — an estimated $3.97M sold.

Marshall Wace first reported a position in APTO in Q4 2020 and held it in 2 quarters. The position peaked at $3.97M in Q1 2021. 63 funds tracked by Wall St. Rank hold APTO as of Q2 2021.

  • Marshall Wace reported no remaining Aptose Biosciences, Inc. position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace sold 1,477 Aptose Biosciences, Inc. shares in Q2 2021, an estimated $3.97M.
  • Marshall Wace first reported a position in Aptose Biosciences, Inc. in Q4 2020 and held it in 2 quarters.
  • Marshall Wace's Aptose Biosciences, Inc. position peaked at $3.97M in Q1 2021.
  • 63 funds tracked by Wall St. Rank held Aptose Biosciences, Inc. as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.